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In the last years miRNAs have increasingly been recognised as potent posttranscriptional regulators of gene expression. Possibly,
miRNAs exert their action on virtually any biological process by simultaneous regulation of numerous genes. The importance of
miRNA-basedregulationinhealthanddiseasehasinspiredresearchtoinvestigatediverseaspectsofmiRNAorigin,biogenesis,and
function. Despite the recent rapid accumulation of experimental data, and the emergence of functional models, the complexity
of miRNA-based regulation is still far from being well understood. In particular, we lack comprehensive knowledge as to which
cellular processes are regulated by which miRNAs, and, furthermore, how temporal and spatial interactions of miRNAs to their
targets occur. Results from large-scale functional analyses have immense potential to address these questions. In this review, we
discuss the latest progress in application of high-content and high-throughput functional analysis for the systematic elucidation of
the biological roles of miRNAs.
1.Introduction
miRNAs (microRNAs) are 17-nt to 24-nt long noncoding
RNAs that regulate gene expression in metazoans. miRNAs
act by partially or completely complementary binding to
their target mRNAs, resulting in translational repression
and/or mRNA degradation [1, 2]. miRNAs are predicted
to aﬀect the expression of nearly 60% of protein-coding
mammalian genes [3, 4]a n d ,t h e r e b y ,t oc o n t r o lm a n y ,i f
not all, biological processes. Fundamental changes at the
cellular and organismal level, including development [5],
aging [6], the stress response [7], cell proliferation [8, 9],
and apoptosis [10, 11], were shown to be regulated by
miRNAs. Furthermore, miRNAs have been implicated in
various diseases, such as diabetes [12–14], cancer [15, 16],
hepatitis C [17], neurodevelopmental (reviewed in [18]),
and mental [19] disorders. Rapidly growing knowledge of
miRNAs as potent regulators in health and disease makes
miRNAs attractive as targets for therapeutic intervention
[20, 21]a sw e l la sf o rd i a g n o s t i cm a r k e r s[ 22, 23].
Numerous previous publications have addressed miRNA
biogenesis and action (for detailed reviews see [24, 25]).
Brieﬂy, miRNAs are transcribed as long primary tran-
scripts (pri-miRNAs), most of which are polyadenylated
and capped. Pri-miRNAs are initially cleaved in nucleus
by a multiprotein complex, called Microprocessor, yielding
∼70-nt long stem-loop structured precursor miRNAs (pre-
miRNAs). The key components of the Microprocessor
complex are the RNase III enzyme Drosha and the double-
stranded RNA-binding protein DGCR8/Pasha [26]. The
excisedpre-miRNAhairpinisthenexportedtothecytoplasm
by Exportin-5 complexed with Ran-GTPase [27]. In the
cytoplasm, the pre-miRNA is further processed to a 20–
22-nt long miRNA/miRNA∗ duplex by a second RNase III
enzyme, Dicer, which is in a complex with the TRBP and
PACT proteins [28, 29]. Subsequently, the miRNA duplex
is unwound by multiple helicases, which may be miRNA-
speciﬁc and may regulate miRNA activity [30, 31]. The
mRNA-targeting miRNA strand (guide strand) is loaded
into the miRNA-induced silencing complex (miRISC). Until
recently, it was assumed that the complementary miRNA∗
strand (passenger strand) is degraded, but there is now
evidence that a substantial cohort of miRNA∗ species is
functionally active [32]. The core components of miRISC
are proteins of the Argonaute (AGO) [33] and GW182
proteinfamilies[34].IndividualmiRNAsmightneedspeciﬁc
maturation steps [35–37].
Once incorporated into miRISC, the miRNA brings the
complex to its target mRNAs by interacting with comple-
mentary binding sites, which can be present in multiple2 Journal of Nucleic Acids
copies [38–40]. Each miRNA can usually aﬀect more than
one transcript and, as a consequence, many proteins simul-
taneously [41, 42]. On the other hand, multiple miRNAs
can repress expression of a single target mRNA [43–46].
miRNAs are postulated to preferentially bind to the 3 
untranslated regions (3 UTRs) of transcripts [47]. However,
recent experimental evidences prove the existence of a new
class of miRNA targets containing miRNA binding sites in
both their 5 UTR and 3 UTR [48] or within the coding
region of mRNA [49].
The complexity of miRNA-mediated modulation of gene
expression is only beginning to be appreciated, and much
research needs to be done in order to understand miRNA
global and adaptive regulatory functions. In this review,
we summarize available methodologies for modulating
expression levels of endogenous miRNAs, as well as on the
application of these strategies for high-content and high-
throughput functional studies.
2. RNA Silencing
The discovery that small ncRNAs (noncoding RNAs) play
pivotal roles in fundamental biological processes has con-
siderably widened our knowledge of mechanisms of gene
regulationinthelastyears[50,51].siRNAs(smallinterfering
RNAs) and miRNAs are the two best characterized classes
of ncRNAs. Both are derived from dsRNA (double-stranded
RNA) precursors and exert their inhibitory function on gene
expression by Watson-Crick base-pairing to complementary
sequences in target RNA molecules: an eﬀect commonly
referred to as gene silencing [2]. Moreover, both siRNAs
and miRNAs share some components of the cellular eﬀector
machinery involved in gene silencing [52]. Usually, miRNAs
modify expression of endogenous genes whereas siRNAs
have evolved to defend genome integrity against foreign
invaders, like viruses or transposons [53]. In mammals
siRNAs are 21-22nt long fragments often, but not always,
derived from foreign dsRNA by Dicer [52, 54]. siRNAs
are incorporated into the siRNA-induced silencing complex
(siRISC) [55] and bind to perfectly matched sequences in
target molecules. Typically, this induces degradation of the
bound RNA, a function called RNAi (RNA interference)
[53], and this property was widely implicated in functional
studies over the last decade (see what follows).
Binding of miRNA to perfectly matched sequences in
mRNA can also result in degradation of the mRNA [56],
but usually, miRNAs bind to sites in mRNAs with only
partial sequence complementarity. This results primarily in
translational repression rather than degradation [57]b u tc a n
also cause secondary nucleolytic degradation of the mRNA
[24]. Conversely, binding of siRNAs to partly unmatched
sequences in mRNAs can result in translational blockade-
potentially interfering with the results from siRNA-based
screening experiments [56].
3.siRNA/shRNA-Based Screens
In the last years RNAi has developed into a powerful tool
for systematic studies of fundamental physiological and
pathological processes. A number of large-scale screens have
been completed, analysing diverse cellular processes. Recent
impressive examples of genome-wide RNAi-based screens in
human cells are provided by the work of Collinet et al. [58],
who performed a high-content survey of genes involved in
endocytosis, and by the study of Neumann et al., who used
time-lapse microscopy in living cells to identify genes that
play a role in cell division [59].
siRNA-based screens have also been performed in several
model organisms. C. elegans and Drosophila are especially
receptive to this type of genetic screening [60]. In C. elegans,
for example, gene silencing can be accomplished by feeding
bacteria that express long dsRNA (about 200–2000-bp-long)
or by providing such dsRNA in the medium [61, 62]. RNAi
in cultured cells of Drosophila can similarly be induced by
adding in vitro transcribed dsRNA to the culture medium
[63]. In mammalian cells, in contrast, short RNA duplexes
of 21–29bp have to be administered, because long dsRNA
evokes a response of the innate immune system, which
ultimately leads to apoptosis [64]. The short siRNAs can
be chemically synthesized or derived from transcribed PCR
products by digestion with recombinant Dicer or bacterial
RNase III (esiRNAs-endoribonuclease-prepared short inter-
fering RNAs) [64, 65]. siRNA-mediated knock-down can
attaincloseto100%reductioninthetargetmRNA.However,
the eﬀectiveness of an individual siRNA is hard to predict
and, therefore, several siRNAs targeting diﬀerent regions of
the target mRNA have to be tested. Some authors suggest
checking 4–6siRNAs per gene to obtain reliable results in a
screening experiment [66].
If stable knock-down is needed or if cells are diﬃcult to
transfect, short hairpin RNAs (shRNAs) can be used. The
sequences encoding the shRNA can be cloned into plasmids
or virus-derived vectors (lenti-, retro-, or adenoviral origin)
[67–69].Inthecaseof“secondgeneration”shRNAs,socalled
shRNA-miRs, the RNAi-triggering small RNA sequence is
cloned into the backbone of a pri-miRNA [70]. This design
principle, together with improved selection ofthe smallRNA
targeting sequence, improves both the production levels of
small RNAs and the silencing eﬃciency. shRNA-miRs can be
clonedintoconstructscarryingdiﬀerentpromotersandused
for tissue-speciﬁc or inducible expression [70].
4. Modulation of miRNA Function as
an Approach for Functional Screening
Clearly, their biological importance per se makes analyses of
miRNA expression and identiﬁcation of their target mRNAs
a focus of the current research. Yet speciﬁc features of
miRNAs give them strong potential as tools in functional
genomics. Firstly, miRNAs are able to change the translation
of hundreds of mRNAs simultaneously and, by doing so,
add another layer of regulation to gene expression [71]. In
fact, miRNAs can inﬂuence the whole biological programs,
including development, apoptosis, proliferation, and diﬀer-
entiation, not only through direct interactions with target
mRNAs but also indirectly by altering expression of, for
example, components of the translation or RNAi machinery
[42].Journal of Nucleic Acids 3
In general, miRNAs eﬀect only subtle modulation of
target gene expression. Their pronounced eﬀect on cellular
behaviour might, therefore, be a consequence of their ability
to inﬂuence multiple genes involved in a single pathway.
Indeed, miRNA-based screens can provide lists enriched
in functionally related targets: for example, a recent RNAi
screen identiﬁed three target genes that phenocopy miR-
19 and cooperate in the regulation of phosphatidylinositol-
3 kinase-mediated survival signalling [72]. miRNA-based
screens and, especially, a combination of miRNA- and
siRNA-based screens, though laborious, might have a clear
advantage over siRNA-based screens alone, since with siR-
NAs, downregulation of only single individual mRNAs is
expected. On the other hand, enrichment of target genes
with speciﬁc functions is not always found using current
bioinformatic prediction tools [73]; therefore, the potential
to organise hits of miRNA-based screens directly into
functional networks is as yet unproven. The fact that a
single mRNA can be inhibited by diﬀerent miRNAs [74]
also means that cellular phenotypes result from synergistic
eﬀects,complicatinginterpretation.Havinganinfrastructure
for large-scale experimentation, complex and previously
unanticipated regulatory patterns might be identiﬁed.
In contrast to the vast number of mRNAs that have
to be knocked-down in comprehensive functional genomic
approaches using siRNAs/shRNAs, the number of miRNAs
that have to be analysed in a genome-wide screen is
relatively low. To date, 1424 miRNAs have been iden-
tiﬁed in the human genome (miRBase database, release
17; http://www.mirbase.org/). Various in silico methods,
developed to predict targets of miRNAs, estimate that
between 10% and 60% of all mRNAs might be inﬂuenced
by miRNAs [3, 4, 75, 76]. Hence, the analysis of the
comparatively small number of miRNAs could, in principle,
cover the function of substantial fraction of human genes.
To modulate the expression of the same number of genes
by siRNA/shRNA would require about 44,000 to 66,000
diﬀerent siRNA/shRNAs, taking into account the need for
multiple reagents targeting the same mRNA (see above).
5. Tools to ModulatemiRNA Function
Here,wewillbrieﬂydescribeapproachesthatarecurrentlyin
use to modulate miRNA function and discuss their potential
and limitations (Table 1). Basically, it is possible either to
interfere with miRNA expression (loss-of-function assays)
or to induce ectopic (over-) expression of miRNA (gain-of-
function).
One possibility for analysis of miRNA would be a com-
plete knock-out. This very precise intervention will result
in a complete loss of function. The resulting phenotypes
are, therefore, often stronger than those seen after knock-
down. For some time, generation of knock-out phenotypes
was feasible in mammals only by exploiting homologous
recombination technology in mice [77]. More recently, germ-
line competent embryonic stem cells have also been estab-
lished in rat, so that homologous recombination can now
be performed in this species as well [78]. The development
of genome editing approaches, using engineered zinc ﬁnger
nucleases, opened up the possibility to extend such analyses
to other organisms and tissue culture cells [79]. Still, a
gene knock-out is laborious and, if the work is given to a
contractor, expensive. Many miRNAs are located in introns
of protein coding genes; so knock-out of a miRNA can
result in simultaneous inactivation of the “host” protein
coding gene with potentially detrimental eﬀects that are
unrelated to miRNA action. Finally, as discussed below, it
is often desirable to downregulate the function of several
miRNAs together, which is not feasible through knock-out.
Interference with multiple miRNAs that are not synthesized
from a single polycistronic gene is much easier to achieve
using a knock-down approach.
The knock-down of miRNAs can be performed by appli-
cation of antisense oligonucleotides (ASOs). Usually, ASOs
exert their eﬀects independently of the cellular silencing
machinery: their potential in biological assays was described
as early as 1978 [80]. Since then, lot of experience has been
gained in the design of stable, speciﬁc, and potent antisense
reagents for research and therapeutic use. Since unmodiﬁed
oligonucleotides are quickly degraded by nucleases when
administered to cells, chemical modiﬁcation is necessary
to enhance stability and potency. (For a review on chem-
ical modiﬁcation used in antisense approaches, see [81].)
Inactivation of complementary RNA can be achieved, for
example, by delivery of DNA oligonucleotides. RNA/DNA
hybrids are then recognized and cleaved by RNase H [82].
Alternatively, oligonucleotides can be coupled to ribozymes
or DNAzymes that inactivate bound RNA by cleavage [81].
FortheinactivationofmiRNAs,RNA-basedoligonucleotides
that do not carry enzymatic activity have gained popularity.
It is not clear whether these oligonucleotides work by
inducing degradation of the targeted miRNA [83]o rb y
forming stable ASO/miRNA heteroduplexes and, thereby,
blocking miRNA function [84, 85].
ASOs and ribozymes that interfere with miRNA
function are commonly referred to as antagomiRs and
antagomiRzymes, respectively, and can be obtained from
commercial sources. In addition, plasmid- and virus-derived
vectorsexistthatbothallowforsimultaneousandpermanent
expression of antogomiRs targeting diﬀerent miRNAs and
permit measurement of expression levels by coexpression of
a ﬂuorescent reporter protein [86].
In principle, miRNA function can be inhibited at dif-
ferent stages [87]. For example, ASOs have been used to
interfere with the maturation of pri-miRNA [88]. Targeted
degradation of pri-miRNAs in the nucleus with RNase H-
based ASOs has also been tried [87]. Strategies to target pri-
miRNAs could have the advantage of combined inhibition
of several miRNAs transcribed from the same polycistronic
gene locus. Experiments with siRNAs targeting the loop
region of pre-miRNA have been reported [89], but the
approach has not acquired much popularity: the loop region
might be diﬃcult to access, leading to ineﬃcient knock-
down of miRNA [87].
With regard to knock-down of protein-coding mRNAs,
siRNA are nowadays in much wider use than ASOs, probably
b e c a u s es i R N A sp r o v i d eam o r ep o t e n ta n de ﬃcient mode4 Journal of Nucleic Acids
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of intervention. In some model organisms, like zebraﬁsh,
however,acertainclassofASOs,called“morpholinos”, isstill
indispensable for knock-down of gene expression and so far
could not be replaced by siRNA-based approaches [90].
More recently, vector constructs have been devised that
contain multiple binding sites for miRNAs, in order to
competewithendogenousmRNAsformiRNAbinding.Such
miRNA sponges appeared to be a versatile tool for miRNA
research [91]. Loya and colleagues analysed phenotypes
when miR-7, miR-8, and miR-9a in Drosophila were down-
regulated by miRNA sponges. The authors found that
miRNA sponges evoked the same phenotype as produced
by homologous recombination, but in a milder form. This
is expected: miRNA sponges do not completely sequester
target miRNAs, because of the competitive binding of
miRNAs to mRNAs. Still, this approach enables not only
simultaneous down-regulation of several miRNAs but also
inducible expression of miRNA sponges in speciﬁc tissues
andatdiﬀerenttimepoints,allowingspatiotemporalanalysis
ofmiRNAfunction.Forinstance,itwaspossibletoassignthe
known role of miR-8 in neuromuscular junction formation
by expression of miRNA sponge that targeted miR-8 in
muscle cells [92].
As an alternative to, or to complement, loss-of-function
studies, miRNA-mimics can be used to achieve de novo or
enhanced expression of miRNA (gain-of-function). miRNA-
mimics can be administered as synthetic small dsRNA with
sequencesidenticaltothoseofendogenousmiRNAs[93,94].
TheyresemblesiRNAmoleculesandarereadilyincorporated
into the cellular RNA silencing machinery. If stable ectopic
expression of miRNA is desired, constructs are at hand
that allow expression of single or multiple miRNAs, and
measurements of miRNA expression level by cotranscription
of ﬂuorescent reporter protein are possible (e.g., [95]). As
for other vector-based constructs, the choice of suitable pro-
motors can render tissue- and/or time-speciﬁc expression of
miRNA-mimics possible. Importantly, molecules mimicking
diﬀerent maturation stages of endogenous miRNAs can be
overexpressed and analysed.
Spatial and temporal regulation of miRNA expression
can also be attained by allosteric ribozymes, riboswitches
[96]. These are modular constructs containing an aptamer
domain (an RNA sequence that speciﬁcally binds a chemical
compound) embedded within a ribozyme and fused to a
pri-miRNA analogue. This construct is functionally inactive
in the absence of the appropriate chemical trigger. Upon
application of the trigger substance (e.g., theophylline in the
case of the cited work) a conformational change is induced
in the ribozyme leading to its activation. The ribozyme will
thencleavethemodularRNAincis,withpri-miRNAreleased
from the construct and processed [96]. The large number
of known aptamers and their endogenous and exogenous
chemical triggers could develop this approach of conditional
RNA interference into a versatile alternative for inducible
vector constructs, especially if toxic side eﬀects in knock-
down or knock-out approaches are of concern [97].
Finally, speciﬁc mRNAs can be released from miRNA-
mediated inhibition by application of target protectors.I n
experiments performed by Choi et al. in zebraﬁsh [98],
morpholino-based ASOs were used, which prevented miR-
430 binding by blocking seed-matched sites and neighbour-
ingnucleotidesintwotargetmRNAs.Inthisway,theauthors
succeeded in speciﬁcally interfering with miR-430-mediated
translational repression. To conduct this type of experiment,
it is necessary to know the targets of the miRNA of interest,
but target protectors can be valuable in target validation and
in characterization of miRNA: mRNA interactions.
6.miRNA-Based FunctionalScreens
The established infrastructure for siRNA/shRNA screens
(i.e., robotics for large-scale sample preparation, automated
data acquisition and analysis, data storage capacities) can
easily be applied for high-throughput studies of miRNA
function. As for siRNA-based screens, lipid-based trans-
fection is most commonly used to achieve a transient
overexpression [99] or inhibition [100]o fm i R N A si nc e l l
culture. A number of screens were completed under con-
ditions of miRNA stable overexpression [40, 45, 101, 102],
achieved by transduction with retroviral vectors encoding
speciﬁc miRNA genes [40]. Alternatively, constitutive over-
expression or down-regulation of non-coding RNAs can
be obtained by adenoviral vector-based systems [69, 103].
The advantages of the reverse transfection method, coupled
with an automatic liquid handling system, have been also
utilized in miRNA-based screens by several groups with a
high success rate [104, 105].
The ﬁrst miRNA was described in the early 1990s [50],
but the initial accumulation of data concerning regulatory
roles was rather slow [106–108]. This in turn delayed
the availability of reagents to modulate the activity of
endogenous miRNAs, and so the ﬁrst functional miRNA-
based screen [100] was completed a couple of years later
than siRNA-based screens [109]. As a consequence, though,
miRNA-based screens could beneﬁt a lot from prior experi-
ence accumulated with siRNA-based screens.
7.BiologicalProcessesAnalysedin
miRNA-Based Screens
A number of miRNA-based screens have been completed
during the last 5 years (Table 2). Two major groups of
biological processes have been investigated so far, namely,
(i) cell viability, proliferation, and apoptosis and (ii) gene
transcription and/or activity regulation.
Numerous miRNAs were shown to inhibit (let-7, miR-
34a, miR-143, miR-145, miR-221, miR-222) [117–121]o rt o
stimulate (miR-21, miR-133) [122, 123] cell proliferation.
Moreover, recent studies demonstrated that a well-studied
cluster of miR-17-92 can act both as oncogenes [124–
127] and as tumour suppressors [9, 128], and these roles
are probably cell type- and/or environment-dependent.
Context-dependent activity was also reported for miR-24:
down-regulation of miR-24 inhibited proliferation of A549
cells but increased growth of HeLa cells [100].
A considerable increase in the numbers of miRNAs
that regulate cell proliferation and apoptosis was obtained6 Journal of Nucleic Acids
Table 2: miRNA-based functional screens.
Model system
Number of
miRNAs
screened
Type of regulation Phenotype
measured Assay Year Reference
HeLa and A549 95 Loss-of-function by
miRNA inhibitors
Cell
proliferation
and apoptosis
Cell counting and
caspase-3/7 activity assay 2005 [100]
Primary hTERT-
immortalized
BJ-EHT ﬁbroblasts
∼450
Gain-of-function by
stable miRNA
expression
Sustained
proliferation miR-Array 2006 [40]
HeLa ∼450
Gain-of-function by
stable miRNA
expression
p27Kip1
regulation
GFP reporter assay and
miR-Array 2007 [45]
MDA-MB-453 187 Gain-of-function by
miRNA precursors
TRAIL-induced
caspase-3
activation
Caspase-3/7 activity assay 2007 [104]
Drosophila clone 8
cells
77/78
miRNA loci
Gain-of-function by
plasmid-based
miRNA expression
Wg signaling
pathway
regulation
Luciferase reporter assay 2007 [110]
Neuroblastoma cell
lines 8
Gain- and
loss-of-function by
miRNA mimics and
inhibitors
Proliferation Change in electrical
impedance 2008 [111]
MCF7 ∼450
Gain-of-function by
stable miRNA
expression
Cell migration Trans-well cell migration
assay 2008 [101]
HeLa 91 Gain-of-function by
miRNA mimics
p53 gene
activity Luciferase reporter assay 2009 [38]
HeLa ∼450
Gain-of-function by
stable miRNA
expression
Per gene family
regulation
GFP reporter assay and
miR-Array 2009 [102]
Primary ovarian
granulosa cells 80 Gain-of-function by
miRNA precursors
Progesterone,
testosterone and
estradiol release
Enzyme immunoassay
(EIA) 2009 [112]
HEK 293 266 Gain-of-function by
miRNA mimics
p21Cip/Waf1
regulation Luciferase reporter assay 2010 [46]
HCT-16 810 Gain-of-function by
miRNA mimics
Cell viability in
t h ep r e s e n c eo f
Bcl-2 family
inhibitor
ABT-263
CellTiter-Glo Luminescent
Cell Viability Assay 2010 [99]
HEK 293T 107 Gain-of-function by
miRNA mimics
p53 gene
regulation Luciferase reporter assay 2010 [39]
HCT116 p53+/+,
H460 and MCF7 5 Gain-of-function by
miRNA precursors
p53 gene
regulation Western blot 2010 [10]
Huh-7 327 Gain-of-function by
miRNA precursors
Lipid droplet
formation and
growth
Immunocytochemistry and
ﬂuorescence microscopy 2010 [105]
Primary ovarian
granulosa cells 80 Gain-of-function by
miRNA precursors
Proliferation
and apoptosis
Immunocytochemistry and
ﬂuorescence microscopy 2010 [113]
DLD-1 319 Gain-of-function by
miRNA precursors Cell viability CellTiter-Glo Luminescent
Cell Viability Assay 2010 [11]
HMEC 328 Gain-of-function by
miRNA precursors Proliferation Fluorescence microscopy 2010 [114]Journal of Nucleic Acids 7
Table 2: Continued.
Model system
Number of
miRNAs
screened
Type of regulation Phenotype
measured Assay Year Reference
MIA PaCa-2 445
Gain-of-function by
stable miRNA
expression
Proliferation Custom-made microarray 2010 [115]
HeLa and HeLa P4 8
Gain- and
loss-of-function by
miRNA precursors
and inhibitors
Cell
proliferation
and traﬃcking
Fluorescence microscopy 2011 [116]
[40, 99, 105] since Cheng et al. reported the ﬁrst large-scale
screen to identify mammalian miRNAs involved in these
processes [100]. In 2007, Ovcharenko et al. performed a
screen with 187 synthetic oligonucleotides to capture the
modulators of TRAIL-induced apoptotic pathway [104].
They found that 34 of tested miRNAs modulate the activity
of caspase-3. Recently, a gain-of-function miRNA-based
screen was completed in human colorectal cancer DLD-
1 cells [11]. By measuring cell viability, authors not only
conﬁrmed function of already known oncogenic miR-
372 and miR-373 [40] but also discovered novel miRNAs
involved in cell proliferation and apoptosis. miR-491 was
among the strongest antiproliferative miRNAs, and further
experimental analysis revealed that it induces apoptosis
via direct down-regulation of antiapoptotic Bcl-xL [129].
miRNAs regulating expression of another member of Bcl-2
protein family, Mcl1, were identiﬁed by screening a library
of 810 human miRNAs for the ability to confer resistance
of cancer cells to ABT-263, an inhibitor of Bcl-2 family
members [99]. Viability measurements of human colorectal
cancer HCT-16 cells transiently transfected with miRNA
mimics revealed 19 miRNAs that sensitized cells to ABT-
263. 15 of these miRNAs showed the same phenotype in
melanoma CHL1 cells. Furthermore, 10 out of 12 strong
sensitizer miRNAs that were analysed for targeting 3 URT
of Mcl1 were conﬁrmed as direct regulators of the gene.
These examples of the screens demonstrate that miRNAs
that modulate sensitivity to chemotherapeutic agents can be
identiﬁed and potentially, in future, used in cancer therapy
[21, 130]. The feasibility of such screens has vastly improved
by the evolution of methods to quantify cell proliferation
from straightforward cell counting [100] to recording of
electrical impedance over 96hours [111].
miRNAs acting on transcription and/or gene activity
regulation are usually identiﬁed in so-called “target-based
screening”. In the most cases, luciferase or green ﬂuorescent
protein(GFP)isfusedtothegeneofinterestandthestrength
of the detected signal is used to gauge the expression or
activity of the test gene [38, 39, 45, 46, 102]. Using a func-
tional genetic approach with stable expression of individual
miRNAs [40], miR-221 and miR-222 were demonstrated to
speciﬁcally regulate expression of tumour suppressor p27Kip1
[45], miR-192/194 cluster-modulate expression of Per gene
family [102].
The repertoire of cellular processes analysed by miRNA
functional screens is expanding rapidly (Table 2). Doing
miRNA-based screens in appropriate cellular contexts, for
instance, for miRNAs regulating steroidogenesis in ovarian
cells [112], and for miRNAs regulating lipid droplet for-
mation in hepatocytes [105] helps to ensure acquisition of
physiologically relevant information.
8. Gain-of-Function versus Loss-of-Function in
miRNA-Based Screens
Although reagents for gain-of-function and loss-of-function
miRNA experiments are available to similar extents, nearly
all reported screens to assess the function of miRNAs utilized
thegain-of-functionapproach(Table 2).Thistrendprobably
arose because of the ease with which ectopic expression of
miRNAs can be conﬁrmed. For instance, exogenous reporter
gene assays [116, 131], qRT-PCR, and Northern blotting
and ribonuclease protection assay [40] are easily applicable
methodstomeasureover-expressionofmiRNAs.Incontrast,
the only assays that have been extensively used so far to
show the inhibition of endogenous miRNA activity have
involved reporters [38, 100, 128, 132]. The popularity of
gain-of-function screens might additionally be explained by
potentially easier evaluation. Over-expression of miRNAs
might induce accentuated phenotypes, which might be not
related to the levels of endogenous miRNAs, whereas the
evaluation of data obtained under the conditions of miRNA
down-regulation is possible only then one knows expression
level of endogenous miRNAs in the test system. Acquisition
of these data sets, therefore, needs thorough additional
experimentation.
9. Fluorescence ScreeningMicroscopy for
miRNA-Based Screens
There are virtually no reasons why the read-out strate-
gies in miRNA-based screens should be diﬀerent from
the ones established in siRNA-based screens. Nevertheless,
we consider ﬂuorescence microscopy screens to be highly
advantageous. Features that make such microscopy ideal
to analyse regulatory potential of miRNAs include the
following: (i) rapid collection of large amount of data, (ii)
feasibility of phenotype multiplexing, (iii) the possibility
to acquire quantitative data on a cell-by-cell basis and/or
population-based basis, and (iv) detection of subtle phe-
notypes [133, 134]. One of the ﬁrst studies applying this8 Journal of Nucleic Acids
technology for functional miRNA studies was by Sirotkin
and colleagues, who reported an immunocytochemistry-
and ﬂuorescence-microscopy-based screen to identify miR-
NAs regulating proliferation and apoptosis [113]. Primary
human ovarian cells were transfected with synthetic miRNA
precursors, and PCNA and cyclin B1 proteins were used
as markers of proliferation. The expression levels of Bax
and caspase-3, in combination with the TUNEL assay, were
used to determine the extent of apoptosis. The power
of technology is demonstrated by another microscopy-
based screen: using automated image analysis and nucleus
classiﬁcation software, a novel antiproliferative activity of
miR-320a was discovered [116]. The screen to identify
miRNAs controlling lipid droplet formation in hepatocytes
[105] illustrated the sensitivity of ﬂuorescence microscopy-
based approach, which was comparable to the laborious
biochemical assay—11 out of 327 transiently overexpressed
human miRNAs were selected via an automated work ﬂow
as the most potent regulators of intracellular lipid content
[105].
10. Validationof HitsinmiRNA-Based Screens
In current screens, the list of primary hits involved in reg-
ulation of a biological pathway can be obtained reasonably
fast, if necessary infrastructure is on place. The primary hit
lists in siRNA/shRNA-based screens are usually validated by
(i) repeating the assay with diﬀerent types of reagents, and
(ii) secondary assays, and (iii) rescue experiments, in which
aphenotypecausedbyknock-downofacertaingeneproduct
is rescued by the over-expression of a construct that cannot
be attacked by siRNA (either due to mutation or because
of origin from another species). Currently, there is no clear
agreement on criteria for successful validation of primary
hit miRNAs, except from reproducing the phenotype with
diﬀerent reagents. Additionally, the eﬀects caused by miRNA
over-expression and down-regulation could be compared.
Since this can be laborious, lists of miRNAs that cause a
particular phenotype in screens may usefully be published
without further analysis [100, 112, 113], allowing follow-up
by others.
In order to perform a follow-up research on hit miRNAs,
prediction of their target genes needs to be done ﬁrst. Many
computational algorithms have been developed over the last
decade to predict miRNA targets [135], and a combination
of multiple algorithms is frequently used to narrow down
the candidates. Interesting strategy was used in the studies of
TRAIL-induced apoptosis when hits of miRNA-based screen
were compared with those of siRNA-based screen in order
to identify plausible interactions between miRNAs and their
target mRNAs [104].
Many of the screens that have been completed so far have
been extended to experimental identiﬁcation and validation
of the targets of the hit miRNAs (Table 3). The most widely
used method to test a direct regulation of gene expression
by miRNAs is based on reporter assays. The 3 UTR, the
5 UTR,orthewholegeneisclonedimmediatelydownstream
of a reporter gene encoding luciferase or ﬂuorescent protein.
The construct is then transiently cotransfected with miRNA
mimics or antimiRs into host cells and luciferase activity or
ﬂuorescenceismeasuredafter24–48hoursofincubation[10,
11, 38, 99, 110]. Additional evidence that the target gene is
directly regulated by an miRNA can be provided by mutating
[38,110]ordeleting[10,101]predictedmiRNAbindingsites
in the 3 UTR of a reporter vector. As controls, the entire
3 UTR can be inserted in the reverse orientation [136]o r
truncated[110].Frequently,qRT-PCRhasbeenusedtoshow
degradation of target mRNAs in miRNA overexpressing cells
[10, 45, 46, 101].
Since miRNAs can execute their regulatory action by
repressing translation and/or promoting mRNA decay of
target genes [137], measurement of the product protein level
is an additional means to validate miRNA action [11, 45, 46].
Biochemical techniques for the isolation of target mRNAs
were also shown to be rewarding [138–140]. Eventually,
the action of miRNA can be tested by down-regulation of
known or putative target genes and monitoring the resulting
phenotypes [72, 105]. Observation of the same phenotype
after both miRNA over-expression and down-regulation of
its putative target genes strengthens evidence that the target
identiﬁcation was valid. Such tests might include down-
regulationofasingletargetaswellasmultipleones.Complex
evaluations are possible if combining several validation
approaches. For example, changes in target protein level
without any changes in a reporter assay would suggest that
the miRNA does not directly target an aﬀected gene but
rather regulates its modulator or the whole pathway [99].
11. Challenges of siRNA-, shRNAs-, and
miRNA-Based Screens
RNAi-based screens have turned to be extremely useful for
studies in various ﬁelds of biology and medicine [59, 141–
143]. A robust assay, careful design of the experiment,
reliable controls, and exhaustive testing of the reagents are
crucial for successfully completing a screen, and several
excellent reviews, describing the planning of RNAi screen
experiments, have been published (e.g., [60, 144–146]). We
will now focus on some practical aspects of siRNA/shRNA-
based screens that could be relevant while performing
miRNA-based screens.
The analysis of siRNA-based screens is often complicated
by oﬀ-targeteﬀects(OTEs):phenotypescausedbyunspeciﬁc
down-regulation of mRNAs. One source of OTEs is partial
homology of siRNAs with unintended mRNAs. A diﬀerent
type of OTE arises from induction of cytokine production
by siRNA/shRNA with certain sequence motifs [147], which
ultimately results in apoptosis. Therefore, in the last years
considerable eﬀort has been invested in improving the
performance of siRNAs/shRNAs. For example, induction of
an interferon response can be mitigated by excluding GU-
rich sequence motifs in siRNA molecules [148]. Speciﬁcity
can be considerably enhanced by altering the chemical
backbone of siRNAs: examples are LNA (locked nucleic
acid) nucleotide analogues or modifying ribosyl groups by
addition of a 2 -O-methyl group at speciﬁc positions [149,
150].Journal of Nucleic Acids 9
Table 3: Validation assays in miRNA-based screens.
Eﬀector miRNA Target genes Validation assay Year Reference
Expressiona Reporterb qRT-PCR ISc siRNAd
miR-372 and -373 LATS2 + + + + 2006 [40]
miR-221 and -222 p27Kip1 + + 2007 [45]
miR-315 Axin and Notum + 2007 [110]
miR-34a Bcl2 and MYCN + 2008 [111]
miR-373 and -520c CD44 + + 2008 [101]
miR-29a,b,c p85α and CDC42 + + 2009 [38]
miR-192 and -194 Per1, 2 and 3 + 2009 [102]
28 miRNAs p21Cip/Waf1 + + 2010 [46]
10 miRNAs MCL1 + 2010 [99]
miR-1285 p53 + + + 2010 [39]
miR-504 p53 + + 2010 [10]
11 miRNAs Multiple genes + 2010 [105]
miR-491 Bcl-xL + + + 2010 [11]
28 miRNAs p21Cip/Waf1 + + 2010 [114]
amRNA expression proﬁling.
b Luciferase and/or GFP reporter assays.
c Immunostaining.
d Recapitulation of miRNA-mediated phenotype by selected siRNAs.
Secondary or even toxic eﬀects caused by transfection
reagents alone and/or in combination with silencing RNA
cannot be completely ruled out. Fortunately, current formu-
lations contain 5 to 10 times less reagents than were required
severalyears ago. Another approachis to pool severalsiRNAs
against the same target, while using reduced amounts of
each. The idea behind this approach is that the target mRNA
will be attacked by all, or the majority of, siRNAs in the
pool,andthespeciﬁcdown-regulationswillactcumulatively,
whereas OTEs of individual siRNAs will be too weak to
aﬀect results. The same concept of improved signal-to-noise
ratio in observed phenotypes forms also the basis for the
application of esiRNAs [65].
Despite these strategies, though, OTEs and unspeciﬁc
secondary eﬀects cannot be avoided completely. It is, there-
fore,essentialtocontrolforboth.Oneoptionistouseseveral
diﬀerent siRNAs to target the same mRNA at independent
sites. The probability that an observed phenotype corre-
sponds to an on-target silencing eﬀect rises with the number
of siRNAs causing the same phenotype [151]. Moreover, it is
of advantage to measure several cellular parameters (e.g., cell
shape and size, number of cells) in a screen. Multiparametric
analysis allows generation phenotypic proﬁles of individual
siRNAs. A high degree of overlap in these proﬁles justiﬁes
strongconﬁdenceinthespeciﬁcityofanobservedphenotype
[58, 151].
One of the most serious concerns in functional screens
is possible oversaturation of the cellular silencing machinery
by exogenous siRNA/shRNA and miRNA mimics. This can
result in derepression of mRNAs that are regulated by
endogenous miRNAs [152, 153]. Various strategies have
been developed to deal with these problems (for a detailed
compilation of strategies see [154]). Brieﬂy, overloading
the cellular RNA silencing machinery can be avoided by
applying the lowest possible amounts of siRNA/shRNA to
the cells. For instance, transcription from RNA Pol II-driven
promotors, and use of inducible constructs, can be useful
t oc o n t r o ll e v e l so fv e c t o r - e n c o d e ds h R N A s[ 70, 155]. Using
vectors derived from adeno-associated virus can also be a
way to induce a moderate level of stable shRNA expression
in cells [21, 156]. Coexpression of AGO-2 has also been
described as an eﬀective approach to overcome the problem
of saturating the RNAi machinery by ectopic siRNA, shRNA,
andmiRNA[157].EnhancedamountsofAGO-2wereshown
to drive RNAi interference toward preferential knock-down
of perfectly matched target mRNAs in diverse mammalian
cell lines. Because, in addition, less siRNA/shRNA was
needed for speciﬁc knock-down, and unspeciﬁc targeting of
mRNAs was signiﬁcantly reduced in the presence of ectopic
AGO-2, the authors suggest that this strategy might result
in reduced rates of false negatives and false positives in
RNAi-based screening approaches. On the other hand, the
suitability of the approach should be tested rigorously, as
AGO-2 was recently shown to play a role in biogenesis of
particular type of miRNAs [36, 37].
Finally, miRNA-based functional screens might suﬀer
from neutral repression, when reduced transcript levels
do not lead to measurable changes in cellular behaviour.
Sometimes, residual protein is still suﬃcient to fulﬁl the
required function; alternatively, feedback mechanisms exist
that compensate functionally for the knock-down [158].
Usually, screens encompass thousands of genes or even
the whole genomes; so it is hardly possible to look for
functions that might be conferred by redundant gene
function. Often, cellular functions are not controlled by just
one protein, but by two or more isotypes or evolutionary-
related forms of proteins to ensure higher reliability of
the process, and metabolic pathways may be redundant.10 Journal of Nucleic Acids
The need to use several siRNAs per protein, and multiple
possible combinations of distinct siRNAs, limits studies
that aim to identify redundant gene products to relatively
small, directed screens. Conversely, highly homologous gene
products, like, for example, splice variants, might have
distinct cellular functions, but siRNAs might target all
forms together (e.g., [159]). Similar concerns pertain to
miRNA-based screens, as redundant activities of miRNAs in
r e g u l a t i o no fm a n yb i o l o g i c a lp r o c e s s e si sw e l ld o c u m e n t e d
[160]: Miska et al. reported that most miRNAs in C. elegans
are individually dispensable [161], and Voorhoeve et al.
found that miR-372 and miR-373 cooperate with oncogenic
RAS in the development of testicular germ cell tumours [40].
A way to deal with miRNA redundancy could be the use
of sensitized genetic backgrounds as described by Brenner
et al. [162]. By deleting one of the two AGO genes in
C. elegans the authors partially disabled the RNA silencing
machinery. In addition, worms with defects in chromatin
modiﬁcation or transcriptional regulation were generated.
Using these organisms allowed deﬁnition of biological roles
for several individual miRNAs [162]. Additionally, synthetic
phenotypes might be used to analyse functions of miRNAs
[160].
The complexity of miRNA action presents a challenging
task for high-throughput functional analysis. However, given
our experience from RNAi screens over the last decade, with
siRNAs and shRNAs in diﬀerent model organisms, careful
experimental design and exhaustive target validation makes
this powerful technology indispensable for understanding
the biological roles of miRNAs.
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